SPYD vs XBI
SPDR Portfolio S&P 500 High Dividend ETF vs SPDR S&P Biotech ETF
- • SPYD has the lower expense ratio at 0.07% vs 0.35% for XBI.
- • SPYD pays a higher dividend yield (4.23%).
Side-by-side metrics
| Metric | SPYD | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.07% | 0.35% |
Dividend yield Trailing 12-month yield. | 4.23% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $7.39B | $8.30B |
YTD return | 9.77% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.72 | 1.09 |
P/E ratio | 17.07 | — |
Last price | $46.73 | $133.66 |
Inception | — | — |
Issuer | State Street | State Street |
SPYD top holdings
| APA | APA Corp | 1.83% |
| LYB | LyondellBasell Industries NV Class A | 1.71% |
| DOW | Dow Inc | 1.70% |
| IRM | Iron Mountain Inc | 1.60% |
| EOG | EOG Resources Inc | 1.55% |
| PSX | Phillips 66 | 1.50% |
| VZ | Verizon Communications Inc | 1.46% |
| TGT | Target Corp | 1.46% |
| OKE | ONEOK Inc | 1.45% |
| SWKS | Skyworks Solutions Inc | 1.43% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About SPYD
SPYD (SPDR Portfolio S&P 500 High Dividend ETF) is Top 80 highest-yielding S&P 500 stocks. Managed by State Street, the fund carries $7.4B in assets under management, an expense ratio of 0.07%, a dividend yield of 4.23%. Its largest holding is APA Corp (APA), which represents 1.8% of the portfolio. Real Estate is the fund's largest sector exposure at 25.8%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.